Nicotine exposure and tardive dyskinesia

@article{Yassa1987NicotineEA,
  title={Nicotine exposure and tardive dyskinesia},
  author={Ramzy Yassa and Samarthji Lal and A. Korpassy and J. R. Raymond Ally},
  journal={Biological Psychiatry},
  year={1987},
  volume={22},
  pages={67-72}
}

Current cannabis use and tardive dyskinesia

Relationship of symptomatology of schizophrenia and tardive dyskinesia

Biological determinants and risk factors for tardive dyskinesia in schizophrenia.

  • R. Sandyk
  • Psychology, Medicine
    The International journal of neuroscience
  • 1993
The study demonstrates that the timing of onset of schizophrenia is a biological determinant for the development of severe TD and postmenopausal schizophrenic patients are at increased risk for TD.

Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.

The prevalence of TD was significantly higher among smokers than non-smokers; however, it was not found that there was an association between the C --> A genetic polymorphism of CYP1A2 and TD.

Tardive dyskinesia in Chinese inpatients with chronic schizophrenia

Risk factors for neuroleptic-induced movement disorders.

A series of studies are presented which demonstrate that the development of these movement disorders may be facilitated by certain risk factors including disturbances in pineal melatonin functions, diabetes mellitus, cognitive deficits, suicidal behavior, and disturbances in the functions of the choroid plexus.

Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management

An overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for Tardive dyskinesia is provided.

Medication-Induced Tardive Dyskinesia: A Review and Update.

The reported incidence of TD seems to be reduced with the use of atypical antipsychotic drugs, yet the risk of developing TD remains with these medications, and the need for a prevention-based focus of TD treatment is highlighted.
...

References

SHOWING 1-10 OF 32 REFERENCES

The pharmacology of tardive dyskinesias.

  • H. Klawans
  • Psychology, Medicine
    The American journal of psychiatry
  • 1973
It has been demonstrated that anticholinergic drugs worsen tardive dyskinesias in patients who have this disorder and that centrally active antICHolinergic agents should not be used as a routine adjunct to neuroleptic therapy.

Elevated Cerebrospinal Fluid Noradrenaline in Tardive Dyskinesia

The hypothesis of noradrenergic hyperactivity, rather than postsynaptic dopamine receptor supersensitivity, in tardive dyskinesia is supported in psychiatric inpatients from Bombay, India.

Psychophysiological reactions to cigarette smoking.

The main effects of smoking were to increase adrenaline output, blood pressure, and heart rate, and to decrease skin temperature and hand steadiness, the changes being consistently more pronounced after the larger dose.

Cigarette smoking and Parkinson disease

There were fewer cigarette smokers among persons with Parkinson disease than among other patients, and significantly different smoking rates were also present at 10 and 20 years before the onset of parkinsonism.

Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program.

It is suggested that there is little reason to exceed 5mg doses of nitrazepam for most patients, particularly those who are elderly, but the elderly are readily susceptible to excessive CNS depression at high doses.

Smoking and Parkinson's disease

A total of 443 patients with Parkinson's disease and a similar number of age and sex matched controls were interviewed as regards their smoking habits. A lower proportion of the patients (26.4 %) had

Smoking and Parkinson's disease.

The negative association between Parkinson's disease and smoking is confirmed and is independent of other associated factors, and the positive correlation of degenerative vascular disease with smoking is further evidence that arteriosclerosis is not involved in the causation of Parkinson's Disease.

Smokers need higher doses of neuroleptic drugs.

It is demonstrated that smokers need higher doses of neuroleptic drugs than nonsmokers and that smoking induces higher enzymatic activity which accelerates the metabolism of many drugs.